Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Mar;22(3):261-72.
doi: 10.1155/2008/493405.

Review and clinical perspectives for the use of infliximab in ulcerative colitis

R Panaccione  1 , R N Fedorak, G Aumais, Edmond-Jean Bernard, C N Bernstein, A Bitton, K Croitoru, L A Dieleman, R Enns, B G Feagan, D Franchimont, G R Greenberg, Anne-Marie Griffiths, J K Marshall, P Pare, S Patel, R Penner, C Render, E Seidman, A Hillary Steinhart
Affiliations
Review

Review and clinical perspectives for the use of infliximab in ulcerative colitis

R Panaccione et al. Can J Gastroenterol. 2008 Mar.

Abstract
in English, French

Infliximab is a chimeric, monoclonal anti-tumour necrosis factor-alpha antibody. It has been previously demonstrated to be an effective treatment for patients with Crohn's disease who do not achieve the desired response with conventional treatments. Although the etiology of ulcerative colitis (UC) differs from that of Crohn's disease, randomized controlled trials have demonstrated that infliximab is also beneficial for the treatment of moderate to severe UC in patients who are either intolerant of or refractory to immunosuppressant agents or steroids, or those who are steroid-dependent. A review of the literature is followed by practical recommendations regarding infliximab that address the needs of clinicians and UC patients. Where there is a lack of evidence-based information, the expert panel provides its combined opinion derived from the members' clinical experiences.

L’infliximab est un anticorps monoclonal chimérique de la tumeur de la nécrose antitumorale alpha. Il a déjà été démontré qu’il s’agit d’un traitement efficace pour les patients atteints de la maladie de Crohn qui ne répondent pas de la manière souhaitée aux traitements classiques. L’étiologie de la colite ulcéreuse (CU) diffère de celle de la maladie de Crohn, mais des essais aléatoires et contrôlés ont démontré que l’infliximab est également bénéfique dans le traitement de la CU modérée à grave chez des patients intolérants ou réfractaires aux immunosuppresseurs ou aux stéroïdes ou stéroïdodépendants. Une analyse bibliographique est suivie de recommandations pratiques au sujet de l’infliximab qui répondent aux besoins des cliniciens et des patients atteints de CU. Lorsqu’on ne possède pas d’information probante, le comité d’experts fournit son opinion collective dérivée de l’expérience clinique des membres.

PubMed Disclaimer

References

    1. Armuzzi A, De Pascalis B, Lupascu A, et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci. 2004;8:231–3. - PubMed
    1. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–11. - PubMed
    1. Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: A randomized pilot study. Eur J Gastroenterol Hepatol. 2004;16:1167–71. - PubMed
    1. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: A randomised controlled trial. Gut. 2003;52:998–1002. - PMC - PubMed
    1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76. - PubMed

Publication types

MeSH terms

LinkOut - more resources